Skip to main
ANRO

ANRO Stock Forecast & Price Target

ANRO Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 71%
Buy 14%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Alto Neuroscience is making significant progress in their clinical-stage assets for treatingeffective treatments for depressive disorders and schizophrenia by leveraging individual neurobiology-based biomarkers.Alto's recent financing extends their cash runway through 2030 to support planned operations and timelines for their clinical trials. With a three-trial program in place, as well as a new monotherapy Phase 3 trial, the company is well-positioned to potentially accelerate their path to a new drug application (NDA) and increase interest in their drugs. Additionally, positive data from the PRIME-PRAXOL trial and the expected readouts from their lead programs could further validate their precision psychiatry model and drive potential upside for the stock.

Bears say

Alto Neuroscience is a clinical-stage biopharmaceutical company with a strong development program but limited financial stability. With cash runway now through 2030, the company's main risks lie in the highly competitive and price-sensitive market for its product candidates. Without significant market traction, the company may struggle to maintain its current valuation and presents a risky investment opportunity for the financial analyst.

ANRO has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 71% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alto Neuroscience Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alto Neuroscience Inc (ANRO) Forecast

Analysts have given ANRO a Strong Buy based on their latest research and market trends.

According to 7 analysts, ANRO has a Strong Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alto Neuroscience Inc (ANRO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.